Five-mRNA Signature for the Prognosis of Breast Cancer Based on the CeRNA Network

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Sep 23

PMID 32964046

Citations 13

Authors

Wenjie Shi

Daojun Hu

Sen Lin

Rui Zhuo

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to investigate the regulatory mechanisms of ceRNAs in breast cancer (BC) and construct a new five-mRNA prognostic signature.

Methods: The ceRNA network was constructed by different RNAs screened by the edgeR package. The BC prognostic signature was built based on the Cox regression analysis. The log-rank method was used to analyse the survival rate of BC patients with different risk scores. The expression of the 5 genes was verified by the GSE81540 dataset and CPTAC database.

Results: A total of 41 BC-adjacent tissues and 473 BC tissues were included in this study. A total of 2,966 differentially expressed lncRNAs, 5,370 differentially expressed mRNAs, and 359 differentially expressed miRNAs were screened. The ceRNA network was constructed using 13 lncRNAs, 267 mRNAs, and 35 miRNAs. Kaplan-Meier (K-M) methods showed that two lncRNAs (AC037487.1 and MIR22HG) are related to prognosis. Five mRNAs (, , , , and ) in the ceRNA network were used to establish a prognostic signature. Survival analysis showed that the prognosis of patients in the low-risk group was significantly better than that in the high-risk group ( = 0.0022). ROC analysis showed that this signature has a good diagnostic ability (AUC = 0.77). Compared with clinical features, this signature was also an independent prognostic factor (HR: 1.206, 95% CI 1.108-1.311; < 0.001). External verification results showed that the expression of the 5 mRNAs differed between the normal and tumour groups at the chip and protein levels ( < 0.001).

Conclusions: These ceRNAs may play a key role in the development of BC, and the new 5-mRNA prognostic signature can improve the prediction of survival for BC patients.

Citing Articles

Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study.

Stopka-Farooqui U, Stavrinides V, Simpson B, Qureshi H, Carmona Echevierra L, Pye H Prostate Cancer Prostatic Dis. 2024; .

PMID: 39578642 DOI: 10.1038/s41391-024-00920-1.

Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.

Zhang X, Zhuge J, Liu J, Xia Z, Wang H, Gao Q Front Immunol. 2023; 14:1153423.

PMID: 37006285 PMC: 10063861. DOI: 10.3389/fimmu.2023.1153423.

Chromatin Regulator-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Breast Cancer.

Feng D, Li W, Wu W, Kahlert U, Gao P, Hu G J Oncol. 2023; 2023:2736932.

PMID: 36755810 PMC: 9902130. DOI: 10.1155/2023/2736932.

MLSP: A bioinformatics tool for predicting molecular subtypes and prognosis in patients with breast cancer.

Zhu J, Kong W, Huang L, Wang S, Bi S, Wang Y Comput Struct Biotechnol J. 2022; 20:6412-6426.

PMID: 36467575 PMC: 9685393. DOI: 10.1016/j.csbj.2022.11.017.

Identification of a Two-lncRNA Signature with Prognostic and Diagnostic Value for Hepatocellular Carcinoma.

Liu H, Zhu J, Guo L, Zhang H, Liu S, Kou X J Oncol. 2022; 2022:2687455.

PMID: 36213826 PMC: 9546683. DOI: 10.1155/2022/2687455.

References

Jiang Y, Lin L, Zhong S, Cai Y, Zhang F, Wang X . Overexpression of novel lncRNA NLIPMT inhibits metastasis by reducing phosphorylated glycogen synthase kinase 3β in breast cancer. J Cell Physiol. 2018; 234(7):10698-10708. DOI: 10.1002/jcp.27738. View

Karreth F, Reschke M, Ruocco A, Ng C, Chapuy B, Leopold V . The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015; 161(2):319-32. PMC: 6922011. DOI: 10.1016/j.cell.2015.02.043. View

Brentnall A, Cuzick J . Risk Models for Breast Cancer and Their Validation. Stat Sci. 2020; 35(1):14-30. PMC: 7100774. DOI: 10.1214/19-STS729. View

Dong Y, Yan W, Zhang S, Zhang M, Zhou Y, Ling H . Prognostic values of long non-coding RNA MIR22HG for patients with hepatocellular carcinoma after hepatectomy. Oncotarget. 2018; 8(69):114041-114049. PMC: 5768384. DOI: 10.18632/oncotarget.23110. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Liu Z, Lu C, Hu H, Cai Z, Liang Q, Sun W . LINC00909 promotes tumor progression in human glioma through regulation of miR-194/MUC1-C axis. Biomed Pharmacother. 2019; 116:108965. DOI: 10.1016/j.biopha.2019.108965. View

Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G . Breast cancer. Lancet. 2005; 365(9472):1727-41. DOI: 10.1016/S0140-6736(05)66546-4. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Vydra N, Janus P, Toma-Jonik A, Stokowy T, Mrowiec K, Korfanty J . 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019; 11(10). PMC: 6826487. DOI: 10.3390/cancers11101533. View

10.

Anastasiadi Z, Lianos G, Ignatiadou E, Harissis H, Mitsis M . Breast cancer in young women: an overview. Updates Surg. 2017; 69(3):313-317. DOI: 10.1007/s13304-017-0424-1. View

11.

Yodsurang V, Tanikawa C, Miyamoto T, Lo P, Hirata M, Matsuda K . Identification of a novel p53 target, COL17A1, that inhibits breast cancer cell migration and invasion. Oncotarget. 2017; 8(34):55790-55803. PMC: 5593524. DOI: 10.18632/oncotarget.18433. View

12.

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

13.

Shi W, Luo Y, Zhao D, Huang H, Pang W . Evaluation of the benefit of post-mastectomy radiotherapy in patients with early-stage breast cancer: A propensity score matching study. Oncol Lett. 2019; 17(6):4851-4858. PMC: 6507476. DOI: 10.3892/ol.2019.10197. View

14.

Fan Y, Sheng W, Meng Y, Cao Y, Li R . LncRNA PTENP1 inhibits cervical cancer progression by suppressing miR-106b. Artif Cells Nanomed Biotechnol. 2020; 48(1):393-407. DOI: 10.1080/21691401.2019.1709852. View

15.

Li H, Wang Y . Long Noncoding RNA (lncRNA) MIR22HG Suppresses Gastric Cancer Progression through Attenuating NOTCH2 Signaling. Med Sci Monit. 2019; 25:656-665. PMC: 6352764. DOI: 10.12659/MSM.912813. View

16.

Zhao S, Fan N, Chen X, Zhuo C, Xu C, Lin R . Long noncoding RNA PVT1-214 enhances gastric cancer progression by upregulating TrkC expression in competitively sponging way. Eur Rev Med Pharmacol Sci. 2019; 23(10):4173-4184. DOI: 10.26355/eurrev_201905_17920. View

17.

Liu Y, Sharma S, Watabe K . Roles of lncRNA in breast cancer. Front Biosci (Schol Ed). 2015; 7(1):94-108. PMC: 5651513. DOI: 10.2741/S427. View

18.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

19.

Jiang H, Liang M, Jiang Y, Zhang T, Mo K, Su S . The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer. Cancer Cell Int. 2019; 19:152. PMC: 6544966. DOI: 10.1186/s12935-019-0872-4. View

20.

De Martino M, Forzati F, Marfella M, Pellecchia S, Arra C, Terracciano L . HMGA1P7-pseudogene regulates H19 and Igf2 expression by a competitive endogenous RNA mechanism. Sci Rep. 2016; 6:37622. PMC: 5118720. DOI: 10.1038/srep37622. View